Why MannKind Shares More Than Doubled This Week
MannKind shares are continuing their rally from Tuesday when it was announced that United Therapeutics was licensing MannKind a dry powder formulation of treprostinil, the active ingredient in Remodulin.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
MannKind Corp. (NASDAQ: MNKD) shares continued their rally from Tuesday when it was announced that United Therapeutics Corp. (NASDAQ: UTHR) was licensing from MannKind a dry powder formulation of treprostinil, the active ingredient in Remodulin.
This collaboration is in an effort to treat pulmonary arterial hypertension.
Under the terms of the agreement, United Therapeutics is responsible for the development, regulatory activities and commercialization, while MannKind is expected to be responsible for the manufacturing of clinical supplies and preliminary commercial supplies.
United Therapeutics is expected to make an upfront payment of $45 million to MannKind, and MannKind would be eligible to receive milestone payments of up to $50 million for achieving development targets. Also, United Therapeutics is expected to pay low double-digit royalties on the product sales.
[nativounit]
Additionally, MannKind granted United Therapeutics an option to expand the license to include other active ingredients for the treatment of pulmonary hypertension. Each optioned product would be subject to the payment to MannKind of up to $40 million in additional option exercise and development milestone payments, as well as a low double-digit royalty on net sales of any such product.
In the most recent short interest report, MannKind had 28.61 million shares short with 8.5 days to cover.
In Tuesday’s session, MannKind shares posted a gain of roughly 89% on over 50 million shares traded.
Shares of MannKind were last seen up about 44% at $3.00 on Wednesday, with a consensus analyst price target of $4.00 and a 52-week trading range of $0.98 to $6.96.
Shares of United Therapeutics were up about 1% at $120.50, with a 52-week range of $100.57 to $152.55.
[recirclink id=490235]
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
